Fred Ashbury, PhD MACE

  • Chief Scientific Officer, VieCure
  • Professor (Adjunct), Department of Oncology, University of Calgary, Alberta, Canda; Dalla Lana School of Public Health, University of Toronto, Ontario, Canada

Fred is a co-founder and Chief Scientific Officer at VieCure. He is responsible for developing and maintaining VieCure’s oncology clinical content, genomic-science knowledge identification and codification, and the design and implementation of diagnostic, treatment, supportive care and post-treatment (survivorship) rules that underpin our platform.
He received his bachelor’s degree from the University of Toronto, his master’s degree from Queen’s University, and his doctorate from York University.  He is a former senior executive with the National Cancer Institute of Canada, Cancer Care Ontario, the Alberta Cancer Board, OpTx Corporation, and BridgeSite Clinical Research.  Fred has consulted in oncology knowledge procurement, synthesis and codification globally. He has mentored oncology practices and networks worldwide to define key performance indicators and quality metrics based on current evidence and practice to establish practice accountability, reporting and quality improvement. 
He is a member of the ASCO; board member for the Multi-National Association of Supportive Care in Cancer (MASCC); Chair of the Clinical Practice Guidelines Committee, MASCC; and member of the University of Swinburne Industry Research Advisory Committee. 
Over his 30-year career, Fred has received research funding from leading granting agencies.  He holds university appointments, including Professor (Adjunct), Dalla Lana School of Public Health at the University of Toronto and Professor (Adjunct) Department of Oncology, University of Calgary. He has published 80+ peer-reviewed articles and reports in oncology services delivery, quality in cancer care, and supportive care.  Fred is the Editor-in-Chief for the top-ranked journal Supportive Care in Cancer and sits on other editorial boards of leading journals.

Paul Bunn, Jr., MD, FASCO

  • Distinguished Professor, James Dudley Chair, University of Colorado, Colorado, USA

Dr. Paul A. Bunn, Jr. is Distinguished Professor and the James Dudley Chair in Cancer Research in the Division of Medical Oncology at the University of Colorado Cancer Center of the Univ. of Colorado School of Medicine, where he has practiced and taught since 1984.
Dr. Bunn received his B.A. from Amherst College in Amherst, Mass., and received his M.D. from Weill Cornell Medical College in New York City. He completed an internship and residency at the University of California San Francisco and a fellowship in medical oncology at the National Cancer Institute (Bethesda) Program. He is board certified in internal medicine and medical oncology. Dr. Bunn served as the Head of the Division of Medical Oncology from 1984-1992 and as the Director of the Univ. of Colorado Cancer Center from 1986-2009.  In the IASLC, Dr. Bunn served on the Board of Directors from 1988 to 1994, President from 1997-2000, and CEO from 2004-2014.  Dr. Bunn was the President of ASCO from 2002-2003. 
The author of hundreds of articles, reviews and book chapters, Dr. Bunn’s research is well known in the cancer world. He focuses primarily on novel therapies for lung cancer. Dr. Bunn has led numerous national and local trials regarding the treatment of lung cancer, and his findings are credited with setting standards in the treatment of the disease.
Dr. Bunn has researched new personalized therapies for lung cancer that cause fewer side effects than traditional, intravenous chemotherapy. He has also studied the genetics of the disease, seeking to learn how gene therapy could be used to combat the disease. He is currently the Principal Investigator on the Specialized Program in Research Excellence in Lung Cancer (SPORE) grant funded by the National Institutes of Health and the National Cancer Institute that aims to expand understanding about the biology of the disease, as well as to find new methods of diagnosis, prevention and treatment.

Jennifer Choi, MD

  • Chief, Division of Oncodermatology, Robert H. Lurie Comprehensive Cancer Center
  • Associate Professor, Dermatology, Feinberg School of Medicine, Northwestern University, Illinois, USA

Dr. Choi is the Chief of the Division of Oncodermatology at Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL. She specializes in providing skin care for patients undergoing cancer treatment. Her expertise includes knowledge in recognizing and managing side effects from chemotherapy that may arise as a result of stem cell or solid organ transplantation, including graft-versus-host disease and advanced skin cancer. She directs the Inpatient Dermatology Consult service for the Cancer Center, as well as the comprehensive skin care and skin cancer surveillance program for high-risk patients and all cancer survivors. She also helps to oversee Northwestern Memorial’s extracorporeal photopheresis unit. Additionally, she is director of clinical research trials investigating the prevention and treatment of toxicities. 
Dr. Choi also specializes in treating patients with skin cancer. She is Co-Leader of the Skin Disease Team and an integral member of the Northwestern Melanoma Unit. For all skin cancer patients, she conducts rigorous screening skin examinations on a regular basis to detect skin cancers and sun damage to optimize prevention and therapy. She is experienced with surgical and non-surgical treatment of skin cancers and precancerous lesions.
Dr. Choi also runs a full medical and surgical dermatology practice and is experienced with the use of complex dermatologic therapies.
Dr. Choi received her BA degree from Harvard University and MD degree from Yale University School of Medicine. She completed her internship in Internal Medicine at Brigham and Women's Hospital/Harvard Medical School and residency in Dermatology at Yale, where she served as Chief Resident.

Sashikant Kulkarni, MS, PhD, FACMG

  • Professor, Molecular and Human Genetics, Baylor College of Medicine, Texas, USA

Dr. Kulkarni is the Chief Scientific Officer (CSO) and Senior Vice President in Baylor Genetics. He is Professor and Vice Chairman for Research in the department of Molecular and Human Genetics at Baylor College of Medicine, Texas.  He trained at Harvard Medical School, Imperial College at London, and at AIIMS, India. He is an ABMGG Board-certified medical geneticist.
In his role as CSO and Sr. VP at Baylor Genetics, Dr. Kulkarni is responsible for developing strategy, overseeing all aspects of lab and ancillary operations. He has been building a dedicated test development team to identify new therapies for both constitutional and somatic disorders.
Previously, he was a at Washington University School of Medicine in St. Louis as the Chief Medical Director of Clinical Genomics and Molecular Pathology and Professor in the departments of Pathology & Immunology, Pediatrics and Genetics. 
Dr. Kulkarni’s major research focus is clinical applications of next-geration sequencing (NGS) to drive precision medicine in oncology. He leads efforts to define standards for NGS in clinical diagnostics through collaboration with the CDC, the Clinical Next-Generation-Sequencing Quality Standards National Working Group, FDA and as co-chairman of Clinical Laboratory Standards Institute (CLSI) for microarray-based genomic diagnostics. He was on the Scientific Advisory Board of NIH Institute – National Institute of General Medical Science’s Coriell Institute, Bina Technologies, Swift Biosciences, Roche Diagnostics, Cancer Genomics Program at Princess Margaret Hospital-Toronto, Horizon Discovery and Transgenomics.
He is the editor-in-chief of Cancer Genetics journal and has co-edited a book “Clinical Genomics-A guide to clinical next-generation sequencing”. He is frequently featured in news media and he has published extensively in peer-reviewed journals such as Cell, Cell Systems, Nature, Nature Genetics, Nature Biotechnology, JAMA and New England Journal of Medicine (NEJM).
 

Lisa Madlensky, PhD, CGC

  • Professor, Molecular Genetics – University of California San Diego, California, USA

Lisa Madlensky is Professor, Division of Medical Genetics, Department of Medicine at the University of California San Diego and Program Director, Family Cancer Genetics Program at Moores UCSD Cancer Center.
Dr. Madlensky has provided cancer genetic counseling services for over 20 years. She has practiced in the United States and Canada and was a founding member of the Familial Cancer Risk group of the National Society of Genetic Counselors (NSGC), establishing cancer genetic counseling as a sub-specialty.
Clinical research themes include clinical genetic testing and follow-up for families with familial cancer risk, the public health implications of cancer genetic testing, quality of life in those at increased risk of cancer, the integration of cancer risk assessment into family practice, and family-level cancer prevention. She also studies the impact of direct-to-consumer genetic testing and the relationship between germline and somatic mutations in cancer.

Howard McLeod, PharmD, BCOP

  • Director of Precision Oncology – Moffitt Cancer Center
  • Professor, College of Medicine & Pharmacy, University of South Florida, Florida, USA

Dr. Howard McLeod is Medical Director of the DeBartolo Family Personalized Medicine Institute at the Moffitt Cancer Center.  He is chair of the Department of Individualized Cancer Medicine and a State of Florida Endowed Chair in Cancer Research.  He is also a Senior Member of the Division of Population Sciences and Professor at the University of South Florida. 
Dr. McLeod is also a 1000 talent scholar of China and a Professor at Central South University in Changsha, China. 
Dr. McLeod is chair of the NHGRI eMERGE network external scientific panel and a recent member of the FDA committee on Clinical Pharmacology and the NIH Human Genome Advisory Council. 
Since 2002, Dr. McLeod has been vice chair for Pharmacogenomics for the major NCI clinical trials group, overseeing the largest oncology pharmacogenomics portfolio in the world. He is one of the founding Editors for JCO: Precision Oncology. 
Howard has received millions of dollars in research grants from major funding agencies and he has published over 550 peer reviewed papers on pharmacogenomics, applied therapeutics, or clinical pharmacology and continues to work to advance individualized medicine.

    Ian Olver, MD, PhD, AM

    • QA Professor (Adjunct), Faculty of Health and Medical Sciences, University of Adelaide, South Australia, Australia

    Professor Ian Olver is a medical oncologist, bioethicist and researcher. He is currently Adjunct Professor in the Faculty of Health and Medical Science at the University of Adelaide. He is a former Director, University of South Australia Cancer Research Institute where he headed a psycho-oncology research team. He was previously CEO of Cancer Council Australia and Clinical Director of the Royal Adelaide Hospital Cancer Center.
    Professor Olver is immediate past President of the Multinational Association of Supportive Care in Cancer and chaired the Australian Health Ethics Committee of the NHMRC for the past 6 years.  His expertise is recognized internationally, including speaking engagements in Africa, Europe, and Asia.
    He has published 302 journal papers, 28 book chapters, 4 books, and edited 4 books including MASCC Textbook of Cancer Supportive Care and Survivorship 1st and 2nd editions. In 2008 he was awarded the Cancer Achievement Award by the Medical Oncology Group of Australia and in 2014 the Gold Medal of Cancer Council Australia for distinguished service in cancer.
    Professor Olver was awarded the prestigious Membership of the Order of Australia (AM) in 2011 “For service to medical oncology as a clinician, researcher, administrator and mentor, and to the community through leadership roles with cancer control organisations.”

    Azra Raza, MD

    • Director, Myelodysplastic Syndrome Center, Department of Medicine, Division of Hematology/Oncology
    • Professor, Medicine, Columbia University, New York, USA

    Dr. Azra Raza is the Chan Soon-Shiong Professor of Medicine and Director of the MDS Center at Columbia University in New York. Previously, she was the Chief of Hematology Oncology and the Gladys Smith Martin Professor of Oncology at the University of Massachusetts. She is considered an international authority on pre-leukemia (MDS) and acute leukemia and is one of those rare physician-scientists who divide their time equally between caring for patients and supervising a state-of- the-art basic research lab which is well-funded by multiple large grants. Dr. Raza started collecting blood and marrow samples on her patients in 1984 and now her Tissue Bank, the largest and oldest in the country with >60,000 samples, is considered a unique national treasure.
    Dr. Raza has published her original clinical and basic research comprising over 300 peer reviewed manuscripts in high profile journals like Nature, NEJM, Cell, Molecular Cell, Cancer Research, Blood, Leukemia. She has published >1000 abstracts, dozens of book chapters and edited a book devoted to MDS.
    She is a sought-after speaker in scientific circles and the recipient of numerous awards including The Hope Award in Cancer Research 2012 (shared with the Nobel Laureate Dr. Elizabeth Blackburn). She was named as one of the 100 Women Who Matter by Newsweek Pakistan. Dr. Raza is a member of the Founder Group designing Breakthrough Developments in Science and Technology with President Bill Clinton and met with Vice President Joe Biden to discuss the Cancer Moonshot initiative at his residence at the Naval Observatory in 2015.

    Luis Rojas-Espaillat, MD

    • Vice President Cancer Service Line – Avera Cancer Institute

    Dr. Luis A. Rojas-Espaillat is a native of the Dominican Republic where he graduated with high honors from medical school.  He completed his postgraduate training in obstetrics and gynecology at Temple University in Philadelphia, Pennsylvania; and successfully accomplished a fellowship in gynecologic oncology at the Cleveland Clinic in Cleveland, Ohio. 
    Dr. Rojas-Espaillat has 12 years experience managing complex gynecologic malignancies by performing innovative surgical procedures for gynecologic cancers, administering novel systemic therapies and developing a passion and expertise for precision oncology in gynecologic cancer management.
    He is the Clinical Vice President for Medical Oncology of the cancer service line at Avera Health, a large not-for-profit health network that operates 6 cancer centers at the Northern Plains in the United States. In addition to this role, he is a member of the board of directors of the Avera Health system.
    Dr. Rojas-Espaillat's expertise in precision gynecologic cancer care has allowed him to have an active role in the development of the provider interface for the artificial intelligence oncology platform VieCure®.    
    Dr. Rojas-Espaillat is an active member of the Society of gynecologic oncology (SGO), is double boarded in obstetrics and gynecology and gynecologic oncology, a member of the South Dakota board of medicine and a clinical associate Professor at the University of South Dakota.  Dr. Rojas resides in Sioux Falls, South Dakota with his wife and 3 boys where he enjoys his family, the outdoors, golfing and cooking.

    Arjun Sahgal, MD, FRCPC

    • Deputy Director, Radiation Oncology – Sunnybrook Health Sciences and Odette Cancer Research Program
    • Professor of Radiation Oncology and Surgery, University of Toronto, Ontario, Canada

    Dr. Arjun Sahgal is Professor of Radiation Oncology and Surgery, at the University of Toronto and Deputy Chief, Department of Radiation Oncology, Odette Cancer Centre Sunnybrook Health Sciences Centre.
    Dr. Sahgal is an internationally recognized clinical and research leader in the field of high precision stereotactic radiation to the brain and spine for both metastases and primary tumors. After training at the University of Toronto in radiation oncology, he completed a radiosurgery fellowship at the University of California San Francisco.
    He has published, as lead or contributor, over 250 peer reviewed papers including in high impact journals like the Journal of Clinical Oncology, Lancet Oncology, and New England Journal of Medicine. He has been the recipient of several distinguished awards and visiting professorships, served as past-meeting chairman and board member of the International Stereotactic Radiosurgery Society (ISRS), and current steering committee member for the AOSpine Tumor Knowledge Forum.
    He is the principle investigator for a national Phase 3 randomized trial (SC-24) evaluating spine SBRT to conventional radiation. Currently, he serves as Deputy Chief of the Department of Radiation Oncology at the University of Toronto affiliated Sunnybrook Odette Cancer Centre. In addition, he is the director of the Sunnybrook Cancer Ablation Therapy (CAT) program including the installation of a MR Brachytherapy suite, MR Linac and Gamma Knife Icon. His next phase of research is in the development of these CAT technologies, integrating MR in radiation therapy, and the application of MR Guided Focused Ultrasound with radiation.

    Keith Thompson, MD

    • Chief Medical Officer, Montgomery Cancer Center, Alabama, USA

    Dr. Thompson has been actively involved in several organizations, including the American College of Physicians, the Montgomery County Medical Society, the Alabama State Medical Society, the Clinical Advisory Committee for Medical Oncology for the State of Alabama, the American Society of Hematology, and the United States Pharmacopoeia Dispensing Information (USPDI) Oncology Advisory Board. He has served as President of the Alabama Society of Clinical Oncology and as Medical Director for Baptist Hospice. He has also served as an associate editor of the Journal of Clinical Oncology, and has a special interest in electronic health records. He currently heads the CancerlinQ committee for the American Society of Clinical Oncology.
    Dr. Thompson graduated from Auburn University summa cum laude and received his Doctor of Medicine degree from Vanderbilt University. He served his internal medicine internship, as well as his hematology / oncology fellowship, at the Medical University of South Carolina.

    Casey Williams, PharmD, BCOP

    • Vice President of Research, Avera Cancer Institute, South Dakota, USA
    • Associate Professor, Internal Medicine, University of South Dakota, South Dakota, USA

    Dr. Williams is the Chief Scientific Officer and the Director of Early Phase Clinical Trials at the Avera Cancer Institute in Sioux Falls, South Dakota. Dr. Williams received his Pharm.D. from Creighton University and subsequently completed his PGY-1 residency in Pharmacy Practice at the University of North Carolina, and his PGY-2 Oncology Practice residency at the University of Texas/Audie Murphy VA.
    Dr. Williams has faculty appointments at the University of Kansas School of Pharmacy, South Dakota State University School of Pharmacy and the University of South Dakota School Of Medicine. He is a fellow of the Hematology/Oncology Pharmacy Association and the past chair of Board of Pharmaceutical Specialties Oncology Specialty Council.
    Dr. Williams has an excess of 100 peer reviewed abstracts and manuscripts and is currently the Principal Investigator of phase 1 clinical trials investigating the role of combination therapy in the treatment of early and advanced malignancies.

    Pradip De, PhD

    • Signal Transduction Pathway Consultant – Viecure
    • Assistant Professor, Department of Internal Medicine at the University of South Dakota, South Dakota, USA

    Dr. Pradip De is a Senior Scientist and Head of Translational Oncology at the Avera Cancer Institute, Center for Precision Oncology, in Sioux Falls, South Dakota. By training, he is a signal transduction biologist.  His primary focus of research is to investigate the signal-processing and resistance mechanisms in tumor cells, especially in subtype-specific breast cancer model.  He is deeply involved in developing a comprehensive precision medicine focused treatment strategy based on actionable genetic alterations of patients’ tumor samples. In his day to day professional life, he tries to strengthen clinical decision-making by aligning specific mutations with targeted drugs on a case to case basis.
    Dr. De is also Assistant Professor in the Department of Internal Medicine at the University of South Dakota, Sanford School of Medicine.  His experiences in the field of signal transduction pathway research include prior appointments at the Emory School of Medicine, pediatric hematology/oncology in the Department of Pediatrics, AFLAC Cancer Center and Blood Disorder Services (in Emory).  He was a post-doctoral research fellow at the Herman B. Wells Center for Pediatric Research, Purdue University.
    Over the course of his 25-year career in cancer research (in both industry and academia), Dr. De has authored more than 50 peer-reviewed articles, editorials and book chapters.  He has presented his research at leading international conferences, including ASCO, the World Wide Innovation Network Annual Meeting, with more than 100 accepted abstracts.  Dr. De reviews original research articles for several journals, including FEBS letters, Cancer Research, Clinical Cancer Research, the British Journal of Cancer, Oncologist and Molecular Cancer Therapeutics